Illumina News and Research

RSS

Fluidigm releases amplicon tagging protocol for Illumina GA II next-generation sequencer

Fluidigm Corporation today announced the release of its amplicon tagging protocol for the Illumina GA II next-generation sequencer. The 48.48 Access Array integrated fluidic circuit (IFC) allows Illumina GA II users to automatically prepare sequencing-ready libraries from 48 individual samples at a time, for as little as $7 (U.S.) per sample.

10 Feb 2010

New England Biolabs to supply Wellcome Trust Sanger Institute next-generation sequencing library construction reagents

As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents.

From New England Biolabs 5 Feb 2010

Study finds link between genes that regulate maternal inflammatory response, bacterial vaginosis and preterm delivery

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will show the use of haplotype tagging (hap-tag) single-nucleotide polymorphisms (SNPs) to study the relationship between genetic predispositions, an environmental factor - bacterial vaginosis, and preterm birth.

4 Feb 2010

Oxford Nanopore Technologies raises $28M in new funding

Oxford Nanopore Technologies Ltd., a privately held company that is developing a disruptive technology platform for the electronic, label-free analysis of single molecules, today announced that it has raised £17.4 million ($28 million) in new funding.

From Oxford Nanopore Technologies 1 Feb 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010

LadaTech files patent infringement lawsuit against Illumina

LadaTech announced today that it has served its complaint upon Illumina, Inc. in its lawsuit for patent infringement in the United States District Court for the District of Delaware. LadaTech is jointly owned by GlaxoSmithKline and IP Finance Holdings.

From Illumina, Inc. 22 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

Illumina's Board of Directors authorize a new stock repurchase program

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.

From Illumina, Inc. 25 Nov 2009

EraGen Biosciences to have access to Illumina’s BeadXpress platform

EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.

From Illumina, Inc. 23 Nov 2009

Second Consumer Genetics Conference to be hosted at the Hynes Convention Center

The media spotlight will shine again on Boston from June 2nd – June 4th, 2010 as the Consumer Genetics Conference, (www.consumergeneticsconference.com), hosts its yearly conference at the Hynes Convention Center.

16 Nov 2009

Broad Institute purchases 30 additional Genome Analyzers from Illumina

Illumina, Inc. today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.

From Illumina, Inc. 6 Nov 2009

Ambry Genetics awarded CSP status for Agilent's SureSelect Target Enrichment System

Agilent Technologies Inc. and Ambry Genetics today announced that Ambry is the first organization to achieve Certified Service Provider (CSP) status for Agilent's SureSelect Target Enrichment System for next-generation sequencing.

23 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Illumina announces 2010 roadmap for Infinium whole-genome genotyping platform

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. today announced its 2010 roadmap for the Infinium whole-genome genotyping platform, offering products capable of analyzing up to five million (5M) variants per sample.

From Illumina, Inc. 22 Oct 2009

New workflow automation system from Illumina

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. announced the launch and immediate availability of cBot, a new standard for ease-of-use and sequencing workflow automation.

From Illumina, Inc. 21 Oct 2009

Illumina and Solexa deny patent infringement allegations

Illumina, Inc. today announced that, together with Solexa its wholly owned subsidiary, it has filed its initial response to the lawsuit brought by Life Technologies and Applied Biosystems on September 21, 2009 in U.S. District Court in Wilmington, Delaware. In their answer, Illumina and Solexa have denied all of Life’s and AB’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.

From Illumina, Inc. 15 Oct 2009

BUSM researchers identify genes that influence the onset age of Parkinson's Disease

Researchers from Boston University School of Medicine (BUSM) have identified genes which may influence the onset age of Parkinson's Disease (PD). The findings, which currently appear on-line in BMC Medical Genetics, are the first to identify genes contributing to the variation in onset age and may help identify mechanisms and therapeutic targets capable of delaying symptoms.

8 Oct 2009

Illumina launches IlluminaCompute for its Genome Analyzer sequencing platform

At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.

From Illumina, Inc. 6 Oct 2009

OICR completes evaluation of NEB's new reagents for use with the Illumina Genome Analyzer

Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II.

From New England Biolabs 1 Oct 2009

Illumina to defend Genome Analyzer System patent infringement suit

Illumina, Inc. today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies Corporation; Applied Biosystems LLC; a Russian research institute; two individuals listed as inventors on the asserted patents; and another individual who appears to have an ownership interest in the patents.

From Illumina, Inc. 28 Sep 2009